GKOSHealthcare · Medical DevicesThe 14 Wall Street analysts covering Glaukos Corp. hold a median 12-month price target of $195 — +19.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Glaukos Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (97): Analysts have, on balance, been raising their forecasts.
Issuance (53): The company has been issuing shares or taking on financing, diluting existing holders.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GKOS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +19.0% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Aug 2026 | BTIG | Maintains | Buy | $193 → $202 |
| 30 July 2026 | BTIG | Maintains | Buy | $164 → $193 |
| 30 July 2026 | BTIG | Maintains | Buy | — |
| 30 July 2026 | Citigroup | Maintains | Buy | — |
| 30 July 2026 | Citigroup | Maintains | Buy | $175 → $188 |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | $168 → $195 |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 July 2026 | Needham | Maintains | Buy | — |
| 30 July 2026 | Needham | Maintains | Buy | $150 → $201 |
| 30 July 2026 | Piper Sandler | Reiterates | Overweight | $165 → $195 |
| 30 July 2026 | Piper Sandler | Reiterates | Overweight | — |
| 30 July 2026 | Stifel | Maintains | Buy | — |
| 30 July 2026 | Stifel | Maintains | Buy | $175 → $190 |
| 30 July 2026 | Truist Securities | Maintains | Buy | $180 → $215 |
| 30 July 2026 | Truist Securities | Maintains | Buy | — |
| 30 July 2026 | UBS | Maintains | Neutral | — |
| 30 July 2026 | UBS | Maintains | Neutral | $150 → $172 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | $138 → $178 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 28 July 2026 | UBS | Assumes | Neutral | $150 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GKOS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Glaukos Corp. returned +90.8% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 10% of US stocks
Cheaper than 7% of US stocks
Cheaper than 98% of US stocks
Higher than 86% of US stocks
Higher than 74% of US stocks
Higher than 92% of US stocks
Higher than 25% of US stocks
Higher than 13% of US stocks
Higher than 29% of US stocks
Higher than 32% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Glaukos Corp. has a market value of $9.5B and an enterprise value of $9.3B.
Revenue in the twelve months to 30 June 2026: $612.8M. The latest quarter grew 49.5% year on year.
Net income over the same four quarters: −$188.0M, a −30.7% net margin.
Diluted earnings per share, trailing twelve months: $−3.25.
Free cash flow in the twelve months to 30 June 2026: −$28.8M.
Trailing P/E: −49.2×; forward P/E: 320.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Glaukos Corp. employs 1,094 people — $560K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Glaukos Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Glaukos (GKOS) reported earnings 30 days ago. According to the report, the stock has risen 8% since its last earnings release, and the article poses the question of whether the rally can continue.
Why it matters — A GKOS watcher would care because the article assesses the stock's post-earnings performance and whether the current upward movement can be sustained.
Glaukos' stock has risen 67% year to date, driven by momentum from its iDose TR product and the launch of Epioxa. The company has raised its 2026 guidance and expanded its ophthalmology platform amid record growth.
Why it matters — GKOS watchers would care because the rally reflects product momentum, higher guidance, and a broader ophthalmology platform that are central to the company's growth trajectory.
A Zacks article recommends retaining Glaukos stock, noting that its iDose TR and Epioxa products are driving rapid growth while margin expansion and a broad pipeline strengthen the company's long-term prospects.
Why it matters — GKOS watchers would care because the piece highlights the growth drivers and pipeline strength underpinning the company's longer-term outlook.
Glaukos Corporation announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on September 9, 2026, at 3:00 p.m. ET in Boston, MA. A live and archived webcast of the events will be available in the Investors section.
Why it matters — The conference participation offers GKOS watchers an opportunity to hear management's remarks and access an archived webcast of the company's presentation.
Glaukos reported a narrower Q2 loss and a 50% revenue increase, driven by iDose TR and Epioxa growth. The company lifted its 2026 sales outlook, and shares rose 9.8%.
Why it matters — GKOS watchers would note the strong revenue growth and raised outlook as signs of commercial momentum for iDose TR and Epioxa.
The 14 Wall Street analysts covering Glaukos Corp. have a median 12-month price target of $195, with estimates ranging from $172 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Glaukos Corp., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Glaukos Corp. 92 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Glaukos Corp. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +19.0% from the last close, and Ticker Nerd's factor model ranks Glaukos Corp. 92 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Glaukos Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GKOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $172 to $225 over the next 12 months.
Glaukos Corp. returned +90.8% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases.
The most recent item we track (Zacks Investment Research, 28 Aug 2026): "Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?". Glaukos (GKOS) reported earnings 30 days ago. According to the report, the stock has risen 8% since its last earnings release, and the article poses the question of whether the rally can continue.
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases. Its product portfolio includes Micro-Invasive Glaucoma Surgery (MIGS) devices, sustained-release drug delivery systems, and bio-activated therapies designed to address chronic eye disease across multiple stages of care. The company serves ophthalmologists, surgeons, and healthcare providers with solutions intended to improve treatment options in both surgical and pharmaceutical settings. Glaukos Corp. is a specialized participant in the eye care market, combining medical devices and medicines to support procedures and therapies used in glaucoma management and corneal health.
CEO Mr. Thomas William Burns · 1,094 employees · United States · https://www.glaukos.com
